 "biotech, research, drug making, science, experiment")
India must strive for ‘biotech sovereignty’ by 2047, a goal that would empower the nation to “ideate, design, engineer, manufacture and regulate its own breakthroughs at global standards,” asserted Biocon executive chairperson Kiran Mazumdar-Shaw at the Bengaluru Tech Summit on Tuesday.
Speaking on the road map for Indian biotechnology, Mazumdar-Shaw highlighted the rapid growth of India’s bioeconomy, which swelled from a mere $10 billion in 2014 to $165 billion in 2024, and is projected to hit $330 billion by 2030. To sustain this trajectory and unlock its full potential, she stated, “We need a quantum leap.”
The path forward hinges
